Back HIV Treatment Experimental HIV Drugs

Experimental HIV Drugs

CROI 2015: Tenofovir Alafenamide as Effective but Safer for Kidneys and Bones than TDF

Tenofovir alafenamide (TAF), a new formulation that has lower concentrations in the blood but reaches higher levels in cells, is as effective as the older version, tenofovir disoproxil fumarate (TDF), according to a report at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) this week in Seattle. A second study showed that TAF has less detrimental effects on the kidneys and bones compared with TDF. TAF has been submitted for approval in the U.S. and Europe.

alt

Read more:

CROI 2015: Putting On Too Much Weight After Starting ART Increases Chronic Inflammation

A return to normal weight after starting antiretroviral therapy (ART) can be beneficial for very sick, underweight individuals living with HIV -- but further weight gain appears to increase markers of inflammation associated with metabolic complications and poorer survival, according to a study reported at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) this week in Seattle.

alt

Read more:

Gilead and Janssen Announce Deal to Develop New TAF Single-Tablet Regimens

Gilead Sciences and Janssen R&D announced an agreement in late December to develop antiretroviral coformulations containing Gilead's novel tenofovir alafenamide (TAF) formulation and emtricitabine plus Janssen's HIV protease inhibitor darunavir (Prezista) or NNRTI rilpivirine (Edurant).

alt

Read more:

CROI 2015: HIV Maturation Inhibitor BMS-955176 Looks Promising In Early Study

A second-generation HIV maturation inhibitor, BMS-955176, demonstrated good safety and high potency, including activity against viral strains that were not susceptible to an earlier drug in this class, researchers reported at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) taking place this week in Seattle.

alt

Read more:

6. HIV Drugs: Few New Approvals, but Pipeline Looks Promising

HIV drug development news in 2014 included approval of a new single-tablet regimen and 2 more components of antiretroviral therapy (ART). Promising candidates in the pipeline include a better-tolerated version of tenofovir, a NNRTI with fewer neuropsychiatric side effects, and potential long-acting injectables that may be useful for treatment or pre-exposure prophylaxis.

alt

Read more: